APA (7th ed.) Citation

Harmatz, P., Prada, C. E., Burton, B. K., Lau, H., Kessler, C. M., Cao, L., . . . Muenzer, J. (2022). First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia B. Molecular therapy, 30(12), 3587-3600. https://doi.org/10.1016/j.ymthe.2022.10.010

Chicago Style (17th ed.) Citation

Harmatz, Paul, et al. "First-in-human In vivo Genome Editing via AAV-zinc-finger Nucleases for Mucopolysaccharidosis I/II and Hemophilia B." Molecular Therapy 30, no. 12 (2022): 3587-3600. https://doi.org/10.1016/j.ymthe.2022.10.010.

MLA (9th ed.) Citation

Harmatz, Paul, et al. "First-in-human In vivo Genome Editing via AAV-zinc-finger Nucleases for Mucopolysaccharidosis I/II and Hemophilia B." Molecular Therapy, vol. 30, no. 12, 2022, pp. 3587-3600, https://doi.org/10.1016/j.ymthe.2022.10.010.